aMVAC.P_012_TURBT_S230
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.650
- INTERFERON_ALPHA_RESPONSE+0.570
- ALLOGRAFT_REJECTION+0.520
- INFLAMMATORY_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.510
- IL6_JAK_STAT3_SIGNALING+0.480
- COAGULATION+0.440
- COMPLEMENT+0.410
- TNFA_SIGNALING_VIA_NFKB+0.410
Top 10 suppressed
- MYC_TARGETS_V2-0.410
- OXIDATIVE_PHOSPHORYLATION-0.360
- DNA_REPAIR-0.330
- E2F_TARGETS-0.330
- MYC_TARGETS_V1-0.250
- G2M_CHECKPOINT-0.240
- ADIPOGENESIS-0.220
- MITOTIC_SPINDLE-0.200
- PEROXISOME-0.190
- FATTY_ACID_METABOLISM-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.914 |
| 2 | BS_G1Y281HX | Neuroblastoma | — | 0.910 |
| 3 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.907 |
| 4 | MDT-AP-2743 | Med | Medulloblastoma | 0.907 |
| 5 | MDT-AP-2869 | Med | Medulloblastoma | 0.905 |
| 6 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.904 |
| 7 | MDT-AP-2936 | Med | Medulloblastoma | 0.904 |
| 8 | BS_W97QQYKQ | Ganglioglioma | — | 0.902 |
| 9 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.897 |
| 10 | sclc0617_S65.txt | — | cohortMD2 | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.650 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |